News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
264,999 Results
Type
Article (13755)
Company Profile (101)
Press Release (251143)
Section
Business (88036)
Career Advice (465)
Deals (15342)
Drug Delivery (67)
Drug Development (36597)
Employer Resources (49)
FDA (6288)
Job Trends (6196)
News (150198)
Policy (14025)
Tag
2024 BioCapital Digital (8)
2024 BioForest Digital (3)
2024 BioForest Standard (1)
2024 BioMidwest Digital (3)
2024 BioMidwest Standard (1)
2024 Bio NC Digital (3)
2024 Bio NC Standard (1)
2024 Biotech Bay Standard (7)
2024 Biotech Beach Digital (4)
2024 Biotech Beach Standard (1)
2024 Genetown Digital (3)
2024 Genetown Standard (3)
2024 Lone Star Bio Digital (2)
2024 Pharm Country Digital (2)
2024 Pharm Country Standard (2)
2025 BioForest Digital (2)
2025 Lone Star Bio Digital (4)
2026 BioCapital Standard (1)
2026 Biotech Bay Standard (1)
2026 Pharm Country Standard (1)
Academia (440)
Adcomms (6)
Allergies (32)
Alliances (23211)
ALS (36)
Alzheimer's disease (384)
Antibody-drug conjugate (ADC) (35)
Approvals (6323)
Artificial intelligence (100)
Autoimmune disease (7)
Automation (3)
Bankruptcy (149)
Best Places to Work (4370)
BIOSECURE Act (9)
Biosimilars (54)
Biotechnology (40)
Bladder cancer (18)
Brain cancer (15)
Breast cancer (74)
Cancer (569)
Cardiovascular disease (67)
Career advice (407)
Career pathing (11)
CAR-T (20)
Cell therapy (81)
Cervical cancer (4)
Clinical research (30843)
Collaboration (319)
Compensation (131)
Complete response letters (16)
COVID-19 (757)
CRISPR (19)
C-suite (112)
Cystic fibrosis (35)
Data (576)
Denatured (15)
Depression (9)
Diabetes (75)
Diagnostics (1315)
Diversity (2)
Diversity, equity & inclusion (13)
Drug discovery (54)
Drug pricing (63)
Drug shortages (12)
Duchenne muscular dystrophy (33)
Earnings (32041)
Editorial (11)
Employer branding (4)
Employer resources (43)
Events (37367)
Executive appointments (346)
FDA (6669)
Featured Employer (20)
Friedreich's ataxia (2)
Frontotemporal dementia (1)
Funding (202)
Gene editing (37)
Generative AI (8)
Gene therapy (97)
GLP-1 (336)
Government (1285)
Grass and pollen (2)
Guidances (15)
Healthcare (3562)
Huntington's disease (4)
IgA nephropathy (9)
Immunology and inflammation (33)
Indications (12)
Infectious disease (788)
Inflammatory bowel disease (54)
Inflation Reduction Act (6)
Influenza (12)
Intellectual property (43)
Interviews (59)
IPO (5874)
IRA (29)
Job creations (2050)
Job search strategy (373)
Kidney cancer (6)
Labor market (10)
Layoffs (177)
Leadership (3)
Legal (3429)
Liver cancer (19)
Lung cancer (75)
Lymphoma (50)
Machine learning (1)
Management (16)
Manufacturing (140)
MASH (30)
Medical device (1273)
Medtech (1275)
Mergers & acquisitions (9652)
Metabolic disorders (243)
Multiple sclerosis (17)
NASH (14)
Neurodegenerative disease (21)
Neuropsychiatric disorders (6)
Neuroscience (544)
NextGen: Class of 2025 (1585)
Non-profit (593)
Northern California (663)
Now hiring (7)
Obesity (140)
Opinion (118)
Ovarian cancer (21)
Pain (49)
Pancreatic cancer (13)
Parkinson's disease (41)
Partnered (5)
Patents (102)
Patient recruitment (28)
Peanut (10)
People (28846)
Pharmaceutical (64)
Pharmacy benefit managers (11)
Phase I (8027)
Phase II (13048)
Phase III (11710)
Pipeline (376)
Podcasts (46)
Policy (58)
Postmarket research (1401)
Preclinical (3206)
Press Release (25)
Prostate cancer (44)
Psychedelics (8)
Radiopharmaceuticals (119)
Rare diseases (156)
Real estate (2633)
Recruiting (17)
Regulatory (10071)
Reports (14)
Research institute (563)
Resumes & cover letters (55)
Rett syndrome (1)
RNA editing (1)
RSV (6)
Schizophrenia (32)
Series A (35)
Series B (11)
Service/supplier (3)
Sickle cell disease (30)
Southern California (678)
Special edition (6)
Spinal muscular atrophy (77)
Sponsored (6)
Startups (1627)
State (2)
Stomach cancer (3)
Supply chain (28)
The Weekly (28)
United States (6727)
Vaccines (149)
Venture capitalists (13)
Webinars (10)
Weight loss (95)
Women's health (8)
Worklife (3)
Date
Today (4)
Last 7 days (189)
Last 30 days (894)
Last 365 days (12042)
2025 (2859)
2024 (12501)
2023 (14246)
2022 (19556)
2021 (20068)
2020 (19032)
2019 (14885)
2018 (11713)
2017 (13888)
2016 (13129)
2015 (15472)
2014 (12419)
2013 (10592)
2012 (11395)
2011 (11922)
2010 (10888)
Location
Africa (313)
Alabama (13)
Alaska (1)
Arizona (53)
Arkansas (3)
Asia (20077)
Australia (2602)
California (1606)
Canada (863)
China (224)
Colorado (65)
Connecticut (65)
Delaware (51)
Europe (39329)
Florida (299)
Georgia (35)
Idaho (9)
Illinois (180)
India (14)
Indiana (127)
Iowa (1)
Japan (83)
Kansas (55)
Kentucky (12)
Maine (2)
Maryland (245)
Massachusetts (1380)
Michigan (27)
Minnesota (89)
Missouri (23)
Montana (8)
Nebraska (6)
Nevada (7)
New Hampshire (6)
New Jersey (699)
New Mexico (7)
New York (466)
North Carolina (374)
North Dakota (2)
Northern California (663)
Ohio (48)
Oklahoma (4)
Oregon (16)
Pennsylvania (405)
Puerto Rico (8)
Rhode Island (7)
South America (501)
South Carolina (2)
Southern California (678)
Tennessee (34)
Texas (215)
Utah (33)
Virginia (69)
Washington D.C. (29)
Washington State (109)
Wisconsin (14)
264,999 Results for "biondvax pharmaceuticals".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Policy
Nasdaq Grants BiondVax Extension to Regain Compliance with Listing Rules
BiondVax Pharmaceuticals Ltd. announced that Nasdaq reviewed BiondVax’s multi-faceted plan to regain compliance with Nasdaq’s Listing Rule 5550 and provided it an extension until October 30, 2023, to demonstrate compliance.
August 1, 2023
·
4 min read
Business
BiondVax Pharmaceuticals Ltd. Rebrands as Scinai Immunotherapeutics Ltd. to Reflect New Focus on Development of Novel Inflammation and Immunology (I&I) Biological Therapeutics
BiondVax Pharmaceuticals Ltd., a biopharmaceutical company, is pleased to announce a change of its corporate name to Scinai Immunotherapeutics Ltd.
September 6, 2023
·
8 min read
BiondVax to Present at Biotech Showcase 2023
BiondVax Pharmaceuticals Ltd. announced that Mr. Amir Reichman, BiondVax’s CEO will present at the Biotech Showcase conference being held Jan. 9-11, 2023.
January 5, 2023
·
4 min read
Business
BiondVax Reports Second Quarter Financial Results and Provides Business Update
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced the publication today of its financial results for the second quarter ended June 30, 2023, and provided a business update.
August 11, 2023
·
9 min read
Business
BiondVax Announces First Quarter 2023 Financial Results and Provides Business Update
BiondVax Pharmaceuticals Ltd. (Nasdaq:BVXV) today published its financial results for the first quarter ended March 31, 2023, and provided a business update.
May 15, 2023
·
7 min read
BiondVax to Present at BIO-Europe Spring
BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland.
March 16, 2023
·
4 min read
Business
Professor Dr. Matthias Dobbelstein joins BiondVax’s Scientific Advisory Board
BiondVax Pharmaceuticals Ltd. today announced that Professor Dr. med. Matthias Dobbelstein has been appointed a member of the company’s Scientific Advisory Board (SAB).
December 6, 2022
·
6 min read
Business
BiondVax Files FY 2022 Financial Statements and Annual Report on Form 10-K and Provides Business Update
BiondVax Pharmaceuticals Ltd. published its full-year financial results for the year ended December 31, 2022, and provided a business update.
April 17, 2023
·
11 min read
Drug Development
BiondVax’s Innovative Inhaled Anti-SARS-CoV-2 NanoAb Virtually Prevented Illness When Administered Prophylactically in Preclinical In Vivo Study
BiondVax Pharmaceuticals Ltd. today announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug.
January 23, 2023
·
9 min read
Deals
BiondVax Regains Nasdaq Compliance
BiondVax Pharmaceuticals Ltd. announces today the receipt of formal notifications from the Nasdaq Stock Market (“Nasdaq”) that the Company has regained compliance with Nasdaq listing rules regarding minimum stockholders’ equity and minimum bid price.
December 12, 2022
·
3 min read
1 of 26,500
Next
